MAPT and Alzheimer disease: Consistent with previous evidence, the group with low Aβ and high NfL (Group 3) did not show elevated tau burden but more severe cortical thinning and a trend toward CVI (as measured by high WMH), adding to the evidence that low Aβ and high neurodegeneration individuals (also known as suspected non‐Alzheimer pathology, or SNAP) are not on the AD pathway (Jack, Knopman, et al. 2016).